San Diego-based genetics company Poseida Therapeutics has secured $142 million in Series C funding, according to company database Crunchbase, topping the city’s recent funding headlines. The cash infusion was announced April 22 and led by Novartis.
According to its Crunchbase profile, "Poseida Therapeutics is a spin out of Transposagen Biopharmaceuticals that utilizes best-in-class, proprietary genome editing technologies to develop targeted, life-saving therapeutics in areas of high unmet medical need. We have demonstrated proof-of-principle that validates the potential of our differentiated genome engineering technologies and their therapeutic applications. Our technology platforms have broad applicability and Poseida’s long-term goal is to apply its proprietary gene editing technologies to a broad range of human diseases."
The four-year-old startup has raised three previous funding rounds, including a $30 million Series B round in 2018.
The round brings total funding raised by San Diego companies in biotechnology over the past month to $148 million, an increase of $126 million from the month before. The local biotechnology industry has seen 53 funding rounds over the past year, securing a total of $2.1 billion in venture funding.
In other local funding news, mobile apps and video games company GoMeta announced a seed funding round on April 16, financed by BITKRAFT Esports Ventures.
According to Crunchbase, "GoMeta allows non-technical individuals and organizations to create, share, and discover interactive content. The platform consists of Metaverse Studio, a drag and drop editor for creating games; Metaverse Browser, a cross-platform mobile application for viewing experiences; the Metaverse embedded SDK; and YAS - Live Gameshow, a real-time app that features the best Metaverse creations for thousands of live players."
Founded in 2016, the company has raised two previous rounds, including a seed round earlier this year.
This story was created automatically using local investment data, then reviewed by an editor. Click here for more about what we're doing. Got thoughts? Go here to share your feedback.
